Is Cboe Global Stock Outperforming the Nasdaq?
Companies with a market value of $10 billion or more are classified as 'large-cap stocks,' Cboe Global holds its place in this category. It leads the U.S. options market and is the originator of the VIX volatility index, giving it a unique edge in volatility-driven trading. Its consistent innovation, regulatory expertise, and scale position it as a key player in capital markets infrastructure, capable of capitalizing on both market volatility and long-term trading trends.
Is Palantir Stock Poised to Surge Amidst the Israel-Iran Conflict?
'It Has No Utility': Warren Buffett Doesn't Care How High Gold Goes, He Isn't a Buyer
OpenAI CEO Sam Altman Says 'We Are Heading Towards a World Where AI Will Just Have Unbelievable Context on Your Life'
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
Cboe Global shares are currently trading 3.6% below its 52-week high of $236.02, which they touched recently on May 8. The stock has climbed 3.6% over the past three months, underperforming the broader Nasdaq Composite's ($NASX) 11.7% rise over the same time frame.
However, on a year-to-date basis, CBOE has delivered a standout performance, surging 16.5% and handily outperforming the Nasdaq's modest 1.2% return. The outperformance extends over the longer horizon as well, with CBOE boasting a 34.4% gain over the past 52 weeks, far exceeding the Nasdaq's 9.4% rise during the same period.
Since July last year, CBOE has remained above its 200-day moving average and has mostly traded over its 50-day moving average since early April.
On May 2, shares of Cboe Global Markets rose over 2% following the release of its Q1 results, which exceeded expectations on both earnings and revenue. The company reported adjusted EPS of $2.50, surpassing consensus estimates by 5.9%, while adjusted revenue came in at $565.2 million, topping forecasts by 1.5%. It upgraded full-year guidance, with revenue growth now projected in the mid-to-high single-digit range, thanks to continued investment in tech platforms, global expansion, and Data Vantage.
CBOE's rival, CME Group Inc. (CME), has outperformed the stock and gained 38.5% over the past 52 weeks and 17.2% in 2025.
Analysts maintain a cautious outlook on its prospects. CBOE has a consensus rating of 'Hold' from the 17 analysts covering the stock and is currently trading above its mean price target of $225.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To provide a brief context, ENFLONSIA happens to be a preventive, long-acting monoclonal antibody (mAb) which has been designed to offer direct, rapid, and durable protection through 5 months, a typical RSV season, with the same 105 mg dose irrespective of weight. Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person's hand holding a bottle of pharmaceuticals. However, ENFLONSIA should not be administered to infants who have a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of ENFLONSIA. Merck & Co., Inc. (NYSE:MRK) added that the approval is basis the results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants. Furthermore, the focus is to ensure the availability of ENFLONSIA in the US before the upcoming RSV season begins. This is to help in reducing the significant burden of the widespread seasonal infection on families and health care systems. Artisan Partners, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
IBIT Covered Calls: 2 Smart Strategies for Crypto-Linked Income
Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase. To trade a covered call we need to own (or buy) 100 shares of a stock and then sell a call option against that stock position. GE Aerospace Bear Put Spread Could Return 208% in the Next Few Months Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook IBIT Covered Calls: 2 Smart Strategies for Crypto-Linked Income Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! The goal is to generate income from the stock holding in addition to any dividends. The premium received from selling the call also covers a small decline in the stock price. However, the trade off is that stock gains are limited above the call option strike price. High volatility stocks have the highest return potential with covered calls, but they also have the highest risk of an adverse price movement. It's all about finding a strategy that fits the investors risk tolerance. iShare Bitcoin ETF Trust (IBIT) is up 26.33% in the last three months and is currently showing implied volatility of 40.21%. Using options, we can generate a significant income from high volatility stocks via a covered call strategy. IBIT Covered Call Example Let's look at two different covered call examples on IBIT stock. The first will use a monthly expiration and the second will use a five-month expiration. Let's evaluate the first IBIT covered call example. Buying 100 shares of IBIT would cost around $6,240. The August 15, 65-strike call option was trading yesterday around $2.73, generating $273 in premium per contract for covered call sellers. Selling the call option generates an income of 4.6% in 44 days, equalling around 37.9% annualized. That assumes the stock stays exactly where it is. What if the stock rises above the strike price of 65? If IBIT closes above 65 on the expiration date, the shares will be called away at 65, leaving the trader with a total profit of $531 (gain on the shares plus the $273 option premium received). That equates to an 8.9% return, which is 73.8% on an annualized basis. Instead of the August call, let's look at selling the December 65-strike call instead. Selling the December 65-strike call option for $7.25 generates an income of 13.1% in 170 days, equalling around 28.2% annualized. If IBIT closes above 65 on the expiration date, the shares will be called away at 65, leaving the trader with a total profit of $983 (gain on the shares plus the $725 option premium received). That equates to a 17.8% return, which is 38.3% on an annualized basis. These figures don't include any potential dividends received during the course of the trades. Of course, the risk with the trade is that the IBIT might drop, which could wipe out any gains made from selling the call. Barchart Technical Opinion The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction. Long term indicators fully support a continuation of the trend. Implied volatility is at 40.21% compared to a 12-month low of 36.80% and a 12-month high of 64.74%. Covered calls can be a great way to generate some extra income from your core portfolio holdings. Please remember that options are risky, and investors can lose 100% of their investment. This article is for education purposes only and not a trade recommendation. Remember to always do your own due diligence and consult your financial advisor before making any investment decisions. On the date of publication, Gavin McMaster did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
26 minutes ago
- Yahoo
Datadog's S&P 500 Debut Sends Shares Soaring
July 3 - Datadog (NASDAQ:DDOG) shares climbed about 9% in after?hours trading on Wednesday, jumping to $149.70, following news that the cloud?monitoring specialist will join the S&P 500. This move comes as part of a quarterly rebalance by S&P Dow Jones Indices. Warning! GuruFocus has detected 4 Warning Sign with DDOG. The index provider said on July 2 that Datadog will replace Juniper Networks (NYSE:JNPR), recently acquired by Hewlett?Packard Enterprise (NYSE:HPE), effective before the market opens on July 9. Inclusion in the S&P 500 often drives demand from passive funds and institutional investors, boosting liquidity and visibility for added names. During regular trading Wednesday, Datadog's stock had already inched up 2%, closing at $135.01. The after?hours surge underscores market sentiment that passive flows and benchmark tracking funds are likely to pour fresh capital into DDOG ahead of the formal switch. With large?cap tech names under pressure recently, Datadog's entry into the S&P 500 may offer a timely lift. Investors will be watching closely as the July 9 rebalancing approaches. Based on the one year price targets offered by 38 analysts, the average target price for Datadog Inc is $139.50 with a high estimate of $200.00 and a low estimate of $115.00. The average target implies a upside of +3.33% from the current price of $135.01. Based on GuruFocus estimates, the estimated GF Value for Datadog Inc in one year is $183.78, suggesting a upside of +36.12% from the current price of $135.01. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
